Related Experiment Video

Updated: Mar 16, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K

Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand

Kareem Bedeir1, Robert P Giugliano1, Basel Ramlawi2

  • 1Brigham and Women's Hospital, Boston, MA, USA.

International Journal of Cardiology
|August 14, 2016
PubMed

Insights

Atrial fibrillation causes one in five strokes. Oral anticoagulants are key for stroke prevention, with newer options offering alternatives to warfarin. Understanding their uses, safety, and limits is vital.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Atrial fibrillation is a significant risk factor, accounting for 20% of all strokes.
  • Anticoagulation therapy is the established standard for mitigating stroke risk in atrial fibrillation patients.
  • Warfarin has been the long-standing treatment, but newer oral anticoagulants have emerged.

Purpose of the Study:

  • To review the current landscape of oral anticoagulants for stroke risk reduction in atrial fibrillation.
  • To provide a comprehensive understanding of the indications, safety, and efficacy profiles of available anticoagulants.
  • To highlight the limitations associated with each therapeutic option.

Main Methods:

  • Systematic literature review of clinical trials and observational studies.
  • Comparative analysis of efficacy and safety data for various oral anticoagulants.
  • Evaluation of guideline recommendations and expert consensus.

Main Results:

  • Multiple oral anticoagulants are now available, each with distinct characteristics.
  • Relative efficacy and safety profiles vary among different agents.
  • Patient-specific factors influence the choice of anticoagulant.

Conclusions:

  • A thorough understanding of each oral anticoagulant's profile is essential for optimal clinical decision-making.
  • Individualized treatment strategies are necessary to maximize stroke prevention while minimizing bleeding risk.
  • Ongoing research is crucial for refining anticoagulant therapy in atrial fibrillation.

Keywords:
Atrial fibrillationBleeding preventionStroke

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.9K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
453
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
537
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
420
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K